by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : July 2009
AusBioPEOPLE Sector on the move Who is where? • Director of Bioprospect and Solagran director and company secretary, Peter Stedwell, passed away on March 30. • Ellex Medical Lasers has appointed John Edwards as general manager of its Australian sales subsidiary, taking over from Simon Luscombe, who was appointed Ellex CEO in late 2008. • Pharmaxis appointed US life science investment manager Richard van den Broek as a director. • Progen appointed Dr Wolf Hanisch as a director. • Tissue Therapies director, Prof David Gardiner, resigned. • Benitec director, Dr Ken Reed, resigned. • Rockeby appointed Eric Wong as a director. • Dr Paul MacLeman resigned as CEO of Hatchtech and took up appointment as CEO of Genetic Technologies. • Avexa appointed Baini as a director. • Tyrian Diagnostics’ director, Phillip Morley, resigned. The biotechnology sector is characterised by upward of one thousand small to medium-sized companies, most of which are in their growth phase. Not surprising, staff members, junior and senior, move frequently around the sector. From March to the end of May, some of the moves include the following: • Actinogen appointed Dr Yvonne Foong as contractual business manager. • Dr Ian Griffiths left the CEO post as Polynovo with Metabolic non-executive director, Iain Kirkwood, named as interim CEO. • Psivida CFO, Michael Soja, resigns, and Ken Ross becomes the principal financial and accounting officer. • Tissue Therapies appointed Mel Bridges as Director. • Xceed Capital replaced company secretary, Adela Richards, with Stephen Belben. • Avexa CFO, Alan Boyd, is replaced by Stephen Kerr, and resigns as a director. • Novogen appointed William D Rueckert as a director. • James Walker has been appointed managing director of Fluorotechnics shortly after being appointed CEO, while executive director and chief sales and marketing officer, Günter Thesseling, resigned. • Dr Robert Caspari stepped down as a director of Living Cell Technologies. • Biosignal’s founder and CEO, Prof Peter Steinberg, resigned. • The Australian Stem Cell Centre has appointed Prof Graham Macdonald as chair and Prof Steve Wesselingh as a director. • Bio-Melbourne Network appointed Anita Petris as an event program manager. • Biosignal appointed Timothy Boyd as a director and announced the departure of three recently appointed directors, Russell Baines, Dr Stewart Washer and Nick Hagan, who will be replaced by Manraj Khosa, Timothy Morrison and Prof Michael Henderson. • Laurent Fossaert appointed acting CEO of Polynovo. • Chemgenex appointed COO, Dr James Campbell as CFO and company secretary, after Rick Merrigan retired. • Arana directors, Gordon Black and Lincoln Chee, resigned and Cephalon appointed its chairman and CEO, Frank Baldino, chairman of Arana and directors Kevin Buchi, Jeffry Vaught, and Lesley Russell. • Helicon director, Dr Arthur Emmett, resigned and will be replaced by company secretary Graeme Boden. • Dr Doug Wilson replaces Joachim (Aki) von Roy as executive chairman of Phylogica. 66 Australasian BioTechnology Volume 19 • Number 2 • July 2009